期刊文献+

脑膜转移癌患者的临床特征及预后因素分析 被引量:6

Clinical features and prognostic factors in patients with leptomeningeal metastases
收藏 分享 导出
摘要 目的探讨脑膜转移癌(LM)患者的临床特点和治疗方法,并进行预后因素分析。方法回顾性分析2002年12月至2011年12月间77例LM患者的临床特征和随访资料,采用Kaplan—Meier法绘制生存曲线,并分析影响LM患者预后的因素。结果77例LM患者的中位生存时间为88d,1年生存率为14.3%(11/77)。单因素分析显示,KPS评分、原发肿瘤控制情况和全身治疗情况与LM患者的生存时间有关(均P〈0.05),全身治疗组和未全身治疗组患者的中位生存时间分别为150d和60d(P=0.001)。全身治疗联合局部治疗(脑脊膜放疗或鞘内化疗)可进一步提高患者的生存时间。多因素分析显示,近期疗效和KPS评分是影响LM患者预后的独立因素(均P〈0.05)。结论KtXS评分和近期疗效是影响LM患者的独立预后因素。全身化疗和(或)靶向治疗可提高LM患者的生存时间,建议首选全身系统治疗(包括全身化疗、靶向治疗)为基础的治疗方案,根据患者具体情况,全身治疗联合全脑放疗或鞘内注射可进一步改善患者预后。 Objective To investigate the clinical characteristics and prognostic factors of leptomeningeal metastases (LM) from solid tumors and to develop better treatment strategies. Methods The clinical characteristics and follow-up results of 77 cases of leptomeningeal metastases ( LM ) from solid tumors diagnosed and treated in our hospital from 2002 to 2011 were retrospectively analyzed. Clinical characteristics, treatment methods and overall survival were analyzed using Kaplan-Meier method and Cox regression model. Results The median survival time for all the patients was 88 days. KPS score, control of the primary tumor and systemic treatment were correlated with survival time for the patients (P 〈 0.05 for all). The median survival time of systemic treatment was 150 d and those without systemic treatment (chemotherapy and/or targeted therapy) after LM was 60 d (P = 0.001 ). Systemic therapy combined with local treatment ( radiotherapy to the meninges or intrathecal chemotherapy) further improved the survival time of patients. Multivariate analysis showed that KPS and short-term therapeutic response for the LM were independent prognostic factors ( P 〈 0.05 for both). Conclusions KPS and short-term therapeutic response are independent prognostic factores for leptomeningeal metastases from solid tumors. Systemic chemotherapy or targeted therapy can prolong the survival time. Systemic treatment (chemotherapy and/or targeted therapy) combined with radiation therapy or intrathecal injection may further improve the clinical outcomes.
作者 李宁 杨渤彦 李峻岭 朱继庆 邹宝华 王延风 于雷 姚晓英 LI Ning , YANC Bo-yan, LI Jun-ling, ZHU Ji-qing, ZOU Bao-hua, WANG Yan-feng, YU Lei, YAO Xiao-ying. Department of General Medicine, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2013年第11期867-870,共4页 Chinese Journal of Oncology
关键词 脑肿瘤 肿瘤转移 药物疗法 放射疗法 预后 Brain neoplasms Neoplasm metastasis Drug therapy Dadiotherapy Prognosis
作者简介 通信作者:杨渤彦,Email:yby6599.yong@vip.sina.com
  • 相关文献

参考文献10

  • 1Pavlidis N. The diagnostic and therapeutic managemeat of leptomeningeal carcinomatosis. Ann Oncol, 2004, 15 Suppl 4:iv285-291. 被引量:1
  • 2Groves MD. New strategies in the management of leptomeningeal metastases. Arch Neural, 2010, 67 : 305-312. 被引量:1
  • 3Waki F, Ando M, Takashima A, et al. Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol, 2009, 93:205-212. 被引量:1
  • 4Clarke JL, Perez HR, Jacks LM, et al. Leptomeingeal metastases in the MRI era. Neurology, 2010, 74:1449-1454. 被引量:1
  • 5Nagpal S, Riess J, Wakelee H. Treatment of leptomeningeal spread of NSCLC: a continuing challenge. Curr Treat Options Oncol, 2012, 13:491-504. 被引量:1
  • 6Boogerd W, van den Bent M J, Koehler PJ, et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomized study. Eur J Cancer, 2004, 40 : 2726-2733. 被引量:1
  • 7Bokstein F, Lossos A, Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer, 1998, 82 : 1756-1763. 被引量:1
  • 8Siegal T. Leptomeningeal metastases: rationale for systerrfic chemotherapy or what is the role of intra-CSF-chemotherapy?. J Neurooncol, 1998, 38 : 151-157. 被引量:1
  • 9Hashimoto N, Imaizumi K, Honda T, et al. Successful re-treat with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer. Lung Cancer, 2006, 53:387-390. 被引量:1
  • 10Kim MK, Lee KH, Lee JK, et al. Gefitinib is also active for carcinomatous meningitis in NSCLC. Lung Cancer, 2005, 50: 265 -269. 被引量:1

同被引文献65

  • 1宋颖博,鹿新红.脑脊液细胞学检查的临床应用[J].兵团医学,2011(4):37-40. 被引量:3
  • 2万崇华 ,陈明清 ,张灿珍 ,汤学良 ,孟琼 ,张晓磬 .癌症患者生命质量测定量表EORTC QLQ—C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:735
  • 3宋孚霞(综述),于国平(审校).脑膜癌病的研究[J].医学综述,2006,12(17):1052-1053. 被引量:4
  • 4邱萌 ,曹丹 ,毕锋.肺癌转移致脑膜癌病的临床分析[J].现代预防医学,2007,34(10):1971-1972. 被引量:3
  • 5Chamberlain M, Soffietti R, Raizer J, et al. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints andresponse criteria of published randomized clinical trialsl-J. Neuro Oncol, 2014,16(9) 1176-1185. 被引量:1
  • 6Grossman SA, Finkelstein DM, Ruckdeschel JC, et al. Ran-domized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group[J]. J Clin On- co1,1993,11(3) .561-569. 被引量:1
  • 7Leal T, Chang JE, Mehta M, et al. Leptomeningeal Metasta- sis: Challenges in Diagnosis and Treatment[J]. Curr Cancer T- her Rev,2011,7(4) 319-327. 被引量:1
  • 8Passarin MG, Sava T, Furlanetto J, et al. Leptomeningeal me- tastasis from solid tumors: a diagnostic and therapeutic challenge [J]. Neurol Sci,2015,36(1) ,117-123. 被引量:1
  • 9Subira D, Serrano C, Castanon S, et al. Role of flow cytometry immunophenotyplng in the diagnosis of leptomeningea[ carcino- matosis['J']. Neuro Oncol, 2012,14( I ) : 43-52. 被引量:1
  • 10Palma J A, Fernandez-Torron R, Esteve-Belloch P, et al. Lep- tomeningeal carcinomatosisz prognostic value of clinical, cere- brospinal fluid, and neuroimaging features[J]. Clin Neurol Neu- rosurg,2013,115(1),19-25. 被引量:1

引证文献6

二级引证文献13

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈